EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ventilatory support and inflammatory peptides in hospitalised patients with COVID-19: A prospective cohort trial

Maximilian Robert Gysan iD, Christopher Milacek, Christina Bal, Andreas Zech, Jonas Brugger, Ruxandra-Iulia Milos, Lukasz Antoniewicz, Marco Idzko, Daniela Gompelmann

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0293532 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Maximilian Robert Gysan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Several studies have shown that SARS-CoV-2 can induce a massive release of cytokines which contributes to disease severity and mortality. Therefore, cytokine levels in the serum may help to predict disease severity and survival in COVID-19 patients.

Methods

In this prospective trial, 88 patients who were hospitalised for COVID-19 were enrolled. Blood samples for serum peptide measurements were taken at the time closest to hospitalisation, at day 5, 9 and 13 (±1). The concentrations of cytokines (IL-1α, IL-1β, IL-1RA, IL-6, L-7, L-10, IFN-γ and TNF-α), chemokines (CCL-3, CCL-4 and CCL-7) and growth factors (G-CSF, GM-CSF and VEGF) were assessed and correlated with the type of ventilation, occurrence of consolidations on imaging and the level of care.

Results

COVID-19 patients (median age 68 years, IQR 55–77) stayed in hospital between 5–171 days. Compared to patients in the general care unit, patients in the intermediate care unit (IMCU) and intensive care unit (ICU) presented significantly elevated serum IL-6 (p = 0.004) and lower IFN-γ levels (p = 0.005), respectively. The peak inspiratory pressure in ventilated patients correlated positively with IL-1RA, G-CSF and inversely with IFN-γ serum levels (all p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansInfantInterleukin 1 Receptor Antagonist ProteinSARS-CoV-2Vascular Endothelial Growth Factor AProspective StudiesInterleukin-6CytokinesGranulocyte Colony-Stimulating FactorOxygen

Substanzen

Interleukin 1 Receptor Antagonist ProteinVascular Endothelial Growth Factor AInterleukin-6CytokinesGranulocyte Colony-Stimulating FactorOxygen

Autor:innen und Institutionen

  • Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
  • Institute for Medical Statistics, Medical University of Vienna, Vienna, Austria.
  • Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Maximilian Robert Gysan

Zitieren

APA

Gysan, M. R., Milacek, C., Bal, C., Zech, A., Brugger, J., Milos, R. I., Antoniewicz, L., Idzko, M., & Gompelmann, D. (2023). Ventilatory support and inflammatory peptides in hospitalised patients with COVID-19: A prospective cohort trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0293532

Vancouver

Gysan MR, Milacek C, Bal C, Zech A, Brugger J, Milos RI, et al. Ventilatory support and inflammatory peptides in hospitalised patients with COVID-19: A prospective cohort trial. PLOS ONE. 2023. doi:10.1371/journal.pone.0293532

BibTeX
@article{Gysan2023,
  author = {Gysan, Maximilian Robert and Milacek, Christopher and Bal, Christina and Zech, Andreas and Brugger, Jonas and Milos, Ruxandra-Iulia and Antoniewicz, Lukasz and Idzko, Marco and Gompelmann, Daniela},
  title = {Ventilatory support and inflammatory peptides in hospitalised patients with COVID-19: A prospective cohort trial},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0293532}
}
Kostenlos starten →